Organisation paid for research Program year 2025 Source: CMS Open Payments

Metroplex Clinical Research Center

Neither a doctor nor a teaching hospital

Research payments

$2,102,612

295 payments

Through program year 2025, Metroplex Clinical Research Center is reported as receiving $2,102,612 in research payments, across 295 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$2,436	1
2024	Research	$15,668	5
2023	Research	$313,665	20
2022	Research	$249,241	58
2021	Research	$431,503	84
2020	Research	$589,645	77
2019	Research	$500,453	50

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $673,924 45 payments
Amgen Inc. $343,636 34 payments
Ucb SA $216,757 13 payments
E.R. Squibb & Sons, L.L.C. $206,730 24 payments
Novartis Pharmaceuticals Corporation $198,090 6 payments
GlaxoSmithKline, LLC. $179,799 109 payments
UCB, Inc. $88,036 1 payment
Pfizer Inc. $64,580 16 payments
Gilead Sciences, Inc. $58,806 14 payments
EMD Serono, Inc. $36,250 21 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus $211,287 7 payments
A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of Ly3471851 (NKTR 358) in Adults With Systemic Lupus Erythematosus $189,352 7 payments
A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis $124,064 4 payments
A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $123,024 55 payments
TARGET: Treatments Against RA and Effect on FDG PET-CT $103,282 2 payments
A Multicenter, Open-Label Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis $88,036 1 payment
A Randomized, Controlled Pragmatic Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $80,174 4 payments
Ph_1b in Subjects with SLE $74,498 2 payments
A Randomized, Two-Arm, Placebo-Controlled, Participant and Investigator-Blinded Study Investigating the Efficacy, Safety and Tolerability of Dfv890 in Patients With Symptomatic Knee Osteoarthritis $73,507 2 payments
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (Sle) $65,881 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.